Fosfomycin: the characteristics, activity, and use in critical care

References

• RazRFosfomycin: an old – new antibioticClin Microbiol Infect2012184710.1111/j.1469-0691.2011.03636.x21914036
   PubMed Web of Science ®Google Scholar
• ThadenJTPogueJMKayeKSRole of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant EnterobacteriaceaeVirulence20166114
   Google Scholar
• SaiprasadPVKrishnaprasadKExploring the hidden potential of fosfomycin for the fight against severe gram-negative infectionsIndian J Med Microbiol201634441610.4103/0255-0857.19537927934817
   PubMed Web of Science ®Google Scholar
• GrifKDierichMPPfallerKMiglioliPAAllerbergerFIn vitro activity of fosfomycin in combination with various antistaphylococcal substancesJ Antimicrob Chemother20014820921711481290
   PubMed Web of Science ®Google Scholar
• TessierFQuentinCIn vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosaClin Microbiol Infec199716159162
   Google Scholar
• DupontHMentecHSolletJPBleichnerGImpact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumoniaIntensive Care Med20012735536210.1007/s00134000064011396279
   PubMed Web of Science ®Google Scholar
• JoukhadarCKleinNDittrichPTarget site penetration of fosfomycin in critically ill patientsJ Antimicrob Chemother20035151247125210.1093/jac/dkg18712668580
   PubMed Web of Science ®Google Scholar
• FrossardMJoukhadarCBurgmannHDistribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissuesAntimicrob Agents Chemother2000442728273210991852
   PubMed Web of Science ®Google Scholar
• Docobo-PérezFDrusanoGLJohnsonAPharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistanceAntimicrob Agents Chemother2015595602561010.1128/AAC.00752-1526124169
   PubMed Web of Science ®Google Scholar
• DijkmansACZacaríasNVBurggraafJFosfomycin: pharmacological, clinical and future perspectivesAntibiotics2017642410.3390/antibiotics6040024
   Web of Science ®Google Scholar
• PopovicMSteinortDPillaiSJoukhadarCFosfomycin: an old, new friend?Eur J Clin Microbiol Infect Dis20102912714210.1007/s10096-009-0833-219915879
   PubMed Web of Science ®Google Scholar
• KahanFMKahanJSCassidyPJKroppHThe mechanism of action of fosfomycin (phosphonomycin)Ann N Y Acad Sci197423536438610.1111/nyas.1974.235.issue-14605290
   PubMed Web of Science ®Google Scholar
• BrownEDVivasEIWalshCTKolterRMurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coliJ Bacteriol19951774194419710.1128/jb.177.14.4194-4197.19957608103
   PubMed Web of Science ®Google Scholar
• SilverLLFosfomycin: mechanism and resistanceCold Spring Harb Perspect Med20177a02526210.1101/cshperspect.a02526228062557
   PubMed Web of Science ®Google Scholar
• KahanFMKahanJSCassidyPJKroppHThe mechanism of action of fosfomycin (phosphonomycin)Ann NY Acad Sci197423536438610.1111/nyas.1974.235.issue-14605290
   PubMed Web of Science ®Google Scholar
• RoussosNKarageorgopoulosDESamonisGFalagasMEClinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infectionsInt J Antimicrob Agents200934650651510.1016/j.ijantimicag.2009.08.01319828298
   PubMed Web of Science ®Google Scholar
• MazzeiTCassettaMIFallaniSArrigucciSNovelliAPharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infectionsInt J Antimicrob Agents200628S35S4110.1016/j.ijantimicag.2006.05.01916829051
   PubMed Web of Science ®Google Scholar
• RibesSTabernerFDomenechAEvaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniaeJ Antimicrob Chemother20065793193610.1093/jac/dkl04716507562
   PubMed Web of Science ®Google Scholar
• PfauslerBSpissHDittrichPZeitlingerMSchmutzhardEJoukhadarCConcentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomyassociated ventriculitisJ Antimicrob Chemother20045384885210.1093/jac/dkh15815056646
   PubMed Web of Science ®Google Scholar
• Hamilton-MillerJMIn vitro activity of fosfomycin against ‘problem’ gram-positive cocciMicrobios199271951031453987
   PubMedGoogle Scholar
• DuezJMMoussonCSiéborEFosfomycin and its application in the treatment of multidrug-resistant Enterobacteriaceae infectionsClin Med Rev Ther20113123142
   Google Scholar
• FrossardMJoukhadarCErovicBMDistribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissuesAntimicrob Agents Chemother2000442728273210991852
   PubMed Web of Science ®Google Scholar
• JoukhadarCKleinNDittrichPTarget site penetration of fosfomycin in critically ill patientsJ Antimicrob Chemother2003511247125210.1093/jac/dkg18712668580
   PubMed Web of Science ®Google Scholar
• KwanKCWadkeDAFoltzELPharmacokinetics of phosphonomycin in Man. I. Intravenous administrationJ Pharm Sci1971606786855125763
   PubMed Web of Science ®Google Scholar
• RoussosNKarageorgopoulosDESamonisGFalagasMEClinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infectionsInt J Antimicrob Agents20093450651510.1016/j.ijantimicag.2009.08.01319828298
   PubMed Web of Science ®Google Scholar
• ReffertJLSmithWJFosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the society of infectious diseases pharmacistsPharmacotherapy20143484585710.1002/phar.143424782335
   PubMed Web of Science ®Google Scholar
• FalagasMEVouloumanouEKSamonisGVardakasKZFosfomycinClin Microbiol Rev20162932134710.1128/CMR.00068-1526960938
   PubMed Web of Science ®Google Scholar
• MichalopoulosASLivaditisIGGougoutasVThe revival of fosfomycinInt J Infect Dis201115e732e73910.1016/j.ijid.2011.07.00721945848
   PubMed Web of Science ®Google Scholar
• Infectopharm Arzneimittel und Consilium GmbHFomicyt Package InsertHeppenheim, GermanyInfectopharm2015
   Google Scholar
• FlorentAChichmanianRMCuaEPulciniCAdverse events associated with intravenous fosfomycinInt J Antimicrob Agents201137828310.1016/j.ijantimicag.2010.09.00221074377
   PubMed Web of Science ®Google Scholar
• DellitTHOwensRCMcGowanJEInfectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardshipClin Infect Dis20074415917710.1086/51039317173212
   PubMed Web of Science ®Google Scholar
• SafdarNHandelsmanJMakiDGDoes combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysisLancet Infect Dis2004451952710.1016/S1473-3099(04)01108-915288826
   PubMed Web of Science ®Google Scholar
• KastorisACRafailidisPIVouloumanouEKGkegkesMatthewIDFalagasESynergy of fosfomycin with other antibiotics for gram-positive and gram-negative bacteriaEur J Clin Pharmacol20106635936810.1007/s00228-010-0794-520186407
   PubMed Web of Science ®Google Scholar
• SamonisGMarakiSKarageorgopoulosDEVouloumanouEKFalagasMESynergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolatesEur J Clin Microbiol Infect Dis20123169570110.1007/s10096-011-1360-521805292
   PubMed Web of Science ®Google Scholar
• GrossatoASartoriRFontanaREffect of non-b-lactam antibiotics on penicillin-binding protein synthesis of enterococcus hirae ATCC 9790J Antimicrob Chemother1991272632712037534
   PubMed Web of Science ®Google Scholar
• TotsukaKUchiyamaTShimizuKKannoYTakataTYoshidaTIn vitro combined effects of fosfomycin and b-lactam antibiotics against penicillin-resistant Streptococcus pneumoniaeJ Infect Chemother19973495410.1007/BF02489184
   Google Scholar
• YamadaSHyoYOhmoriSOhuchiMRole of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosaChemotherapy20075320220910.1159/00009841917356268
   PubMed Web of Science ®Google Scholar
• OkazakiMSuzukiKAsanoNEffectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assayJ Infect Chemother20028374210.1007/s10156020000411957118
   PubMedGoogle Scholar
• TessierFQuentinCIn vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosaEur J Clin Microbiol Infect Dis1997161591629105845
   PubMed Web of Science ®Google Scholar
• Martinez-MartinezLRodriguezGPascualASuárezAIPereaEJIn vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumanniiJ Antimicrob Chemother1996381107110810.1093/jac/38.6.11079023661
   PubMed Web of Science ®Google Scholar
• SantimaleeworagunWWongpoowarakPChayakulPPattharachayakulSTansakulPGareyKWIn vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemasesSoutheast Asian J Trop Med Public Health20114289090022299471
   PubMed Web of Science ®Google Scholar
• InouyeSWatanabeTTsuruokaTKitasatoIAn increase in the antimicrobial activity in vitro of fosfomycin under anaerobic conditionsJ Antimicrob Chemother19892465766610.1093/jac/24.5.6572599990
   PubMed Web of Science ®Google Scholar
• YanagidaCItoKKomiyaIHorieTProtective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissueChem Biol Interact200414813914710.1016/j.cbi.2004.05.00515276870
   PubMed Web of Science ®Google Scholar
• NakamuraTKokuryoTHashimotoYInuiKIEffects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in ratsJ Pharm Pharmacol19995122723210217324
   PubMed Web of Science ®Google Scholar
• Castaneda-GarciaABlazquezJRodriguez-RojasAMolecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistanceAntibiotics2013221723610.3390/antibiotics202021727029300
   PubMedGoogle Scholar
• TsuruokaTYamadaYCharactertization of spontaneous fosfomycin (phosphonomycin)-resistant cells of Escherichia coli B in vitroJ Antibiot19752890691110.7164/antibiotics.28.9061104551
   PubMed Web of Science ®Google Scholar
• KadnerRJWinklerHHIsolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coliJ Bacteriol19731138959004347928
   PubMed Web of Science ®Google Scholar
• KimDHLeesWJKempsellKELaneWSDuncanKWalshCTCharacterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycinBiochemistry1996354923492810.1021/bi952937w8664284
   PubMed Web of Science ®Google Scholar
• HoriiTKimuraTSatoKShibayamaKOhtaMEmergence of fosfomycin-resistant isolates of shiga-like toxin-producing Escherichia coli O26Antimicrob Agents Chemother19994378979310.1128/AAC.43.4.78910103182
   PubMed Web of Science ®Google Scholar
• RigsbyREFillgroveKLBeihofferLAArmstrongRNFosfomycin resistance proteins: A nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamilyMethods Enzymol200540136737916399398
   PubMed Web of Science ®Google Scholar
• KobayashiSKuzuyamaTSetoHCharacterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coliAntimicrob Agents Chemother20004464765010681332
   PubMed Web of Science ®Google Scholar
• KuzuyamaTKobayashiSO’HaraKHidakaTSetoHFosfomycin monophosphate and fosfomycin diphosphate, two inactivated fosfomycin derivatives formed by gene products of fomA and fomB from a fosfomycin producing organism Streptomyces wedmorensisJ Antibiot19964950250410.7164/antibiotics.49.5028682732
   PubMed Web of Science ®Google Scholar
• FarhadiTHashemianSMRComputer-aided design of amino acid-based therapeutics: A reviewDrug Des Devel Ther2018121239125410.2147/DDDT.S159767
   PubMed Web of Science ®Google Scholar
• FarhadiTFakharianAHashemianSMAffinity improvement of a humanized antiviral antibody by structure-based computational designInt J Pept Res Ther2017251181186
   Web of Science ®Google Scholar
• FarhadiTRanjbarMMDesigning and modeling of complex DNA vaccine based on MOMP of Chlamydia trachomatis: an in silico approachNetw Model Anal Health Inform Bioinforma20176110.1007/s13721-016-0142-5
   Web of Science ®Google Scholar
• FarhadiTOvchinnikovRSRanjbarMMIn silico designing of some agonists of toll-like receptor 5 as a novel vaccine adjuvant candidatesNetw Model Anal Health Inform Bioinforma2016531s1310.1007/721-016-0138-1
   Google Scholar
• FarhadiTNezafatNGhasemiYIn silico phylogenetic analysis of Vibrio cholera isolates based on three housekeeping genesInt J Comput Biol and Drug Des201581627410.1504/IJCBDD.2015.06878925869320
   PubMedGoogle Scholar
• HashemianSMRFarhadiTGanjparvarMLinezolid: a review of its properties, function, and use in critical careDrug Des Devel Ther20182018121759176710.2147/DDDT.S164515
   Web of Science ®Google Scholar
• FarhadiTHashemianSMRConstructing novel chimeric DNA vaccine against Salmonella enterica based on SopB and GroEL proteins: an in silico approachJ Pharm Invest2018486639655
   Google Scholar
• FarhadiTFakharianAOvchinnikovRSVirtual screening for potential inhibitors of CTX-M-15 protein of Klebsiella pneumoniaeInterdiscip Sci: Comput Life Sci2018104694703
   PubMed Web of Science ®Google Scholar
• FarhadiTIn silico designing of peptide inhibitors against pregnane X receptor: the novel candidates to control drug metabolismInt J Pept Res Ther2018243409420
   Web of Science ®Google Scholar
• HyattJMMcKinnonPSZimmerGSSchentagJJThe importance of pharmacokinetic/pharmacodynamics surrogate markers to outcome. Focus on antibacterial agentsClin Pharmacokinet19952814316010.2165/00003088-199528020-000057736689
   PubMed Web of Science ®Google Scholar
• SchentagJJNixDEAdelmanMHMathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycinDICP: Ann Pharmacother1991251050105710.1177/106002809102501003
   PubMedGoogle Scholar
• CrokaertFPharmacodynamics, a tool for a better use of antibiotics?Intensive Care Med20012734034310.1007/s00134010086511396276
   PubMed Web of Science ®Google Scholar
• JoukhadarCFrossardMMayerBXImpaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shockCrit Care Med20012938539110.1097/00003246-200102000-0003011246321
   PubMed Web of Science ®Google Scholar
• BrunnerMPernerstorferTMayerBXEichlerHGMüllerMSurgery and intensive care procedures affect the target site distribution of piperacillinCrit Care Med2000281754175910.1097/00003246-200006000-0000910890614
   PubMed Web of Science ®Google Scholar
• JoukhadarCKleinNMayerBXPlasma and tissue pharmacokinetics of cefpirome in patients with sepsisCrit Care Med2002301478148210.1097/00003246-200207000-0001312130965
   PubMed Web of Science ®Google Scholar
• De La PenaADalla CostaTTaltonJDPenetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in ratsPharm Res2001181310131411683245
   PubMed Web of Science ®Google Scholar
• TegederISchmidtkoABräutigamLKirschbaumAGeisslingerGLötschJTissue distribution of imipenem in critically ill patientsClin Pharmacol Ther200271532533310.1067/mcp.2002.12252612011818
   PubMed Web of Science ®Google Scholar
• AsuphonOMontakantikulPHoungsaitongJKiratisinPSonthisombatPOptimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulationInt J Infect Dis201650232910.1016/j.ijid.2016.06.01727418581
   PubMed Web of Science ®Google Scholar